Ixekizumab-induced interstitial lung disease: a case report confirmed by transbronchial lung cryobiopsy
Background: Ixekizumab, an interleukin-17A (IL-17A) inhibitor used in psoriasis treatment, has been linked to drug-induced interstitial lung disease (DI-ILD). The pathophysiological mechanisms and histopathological features of this adverse effect remain poorly documented.Case Presentation: A 69-year...
保存先:
| 主要な著者: | , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Taylor & Francis Group
2024-12-01
|
| シリーズ: | Journal of Dermatological Treatment |
| 主題: | |
| オンライン･アクセス: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2424338 |
| タグ: |
タグなし, このレコードへの初めてのタグを付けませんか!
|